PHARMA MAR
-
EUR
(-)
- 15 min delayed data - Spain Stocks
| Open: | - |
| Change: | - |
| Volume: | - |
| Low: | - |
| High: | - |
| High / Low range: | - |
| Type: | Stocks |
| Ticker: | PHM |
| ISIN: | ES0169501022 |
PHARMA MAR news, videos and press releases - Page 3
For more news please use our advanced search feature.
PHARMA MAR - More news...
PHARMA MAR - More news...
- 12/22/2016 - 08:24 PharmaMar and Chugai Pharmaceutical Enter into a License and Commercialization Agreement for PM1183 in Japan
- 12/01/2016 - 08:00 PharmaMar Presents Positive Results With Its Conjugated Antibody MI130110 in CD13-Expressing Tumor-Cells
- 11/28/2016 - 09:05 PharmaMar Begins a Phase I Study of PM1183 in Japan for the Treatment of Solid Tumors
- 11/16/2016 - 08:45 PharmaMar Appoints Pascal Besman as Chief Operating Officer of PharmaMar U.S.
- 10/31/2016 - 09:00 PharmaMar is Present at the 16th International Gynecologic Cancer Society Meeting With New Evidence on Yondelis®
- 10/28/2016 - 08:45 The EMA Accepts to Assess the Marketing Authorization Application from PharmaMar for Aplidin®
- 10/24/2016 - 03:00 PharmaMar Announces the Opening of a New Affiliate in Austria
- 10/18/2016 - 09:00 PharmaMar Completes the Patient Recruitment for the "CORAIL" Phase III Pivotal Study With PM1183
- 10/10/2016 - 09:00 PharmaMar Announces Positive Results From its Phase II Study With lurbinectedin in BRCA 1/2 - Associated Metastatic Breast Cancer at the ESMO 2016 Congress
- 10/05/2016 - 09:00 PharmaMar Shows New Clinical Data on Yondelis® and Lurbinectedin at ESMO 2016
- 10/04/2016 - 09:00 PharmaMar and Boryung Pharm Sign a Licensing Agreement for Aplidin® (plitidepsin) in Korea
- 09/22/2016 - 09:00 PharmaMar Submits MAA to EMA for Aplidin® for the Treatment of Multiple Myeloma
- 08/02/2016 - 09:00 PharmaMar Initiates a Pivotal Phase III ATLANTIS Study with PM1183 in Combination with Doxorubicin in Patients with Small Cell Lung Cancer
